EW

$84.27

Post-MarketAs of Mar 17, 8:00 PM UTC

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$84.27
Potential Downside
56.9%
Whystock Fair Value$36.33
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive re...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$48.94B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
46.56
Beta
Defensive asset. Lower volatility than the S&P 500.
0.93
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
10.35%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
2.83

Recent News

Zacks
Mar 17, 2026

Should You Continue to Hold Bio-Techne Stock in Your Portfolio?

TECH expands via acquisitions and global growth, but biotech funding softness, U.S. academic spending pressure and competition cloud near-term outlook.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Simply Wall St.
Mar 16, 2026

Edwards Lifesciences (EW) Valuation Check After Recent Share Price Momentum

What Edwards Lifesciences stock’s recent move might be telling you Edwards Lifesciences (EW) has attracted attention after a 2.1% daily gain, set against mixed recent returns including a roughly 10.1% rise over the past month and a small decline over the past 3 months. See our latest analysis for Edwards Lifesciences. At a share price of $83.56, Edwards Lifesciences pairs a 10.1% 1 month share price return with a 2.1% year to date decline, while its 1 year total shareholder return sits at...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 16, 2026

Should You Continue to Hold Integra Stock in Your Portfolio Now?

IART faces macro headwinds and tight liquidity, but strong demand in its Codman Specialty Surgical unit and expanding international launches could support growth.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Mar 15, 2026

This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares

This biotech firm develops therapies targeting cystic fibrosis, with shares up nearly 90% year-over-year as of the latest filing.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Mar 15, 2026

This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per Share

RAPT Therapeutics develops oral therapies for cancer and inflammation, with key drug candidates currently in clinical trials.

BEARISH
Negative press. News cycle fixated on risk factors or misses.